4SC AG — Regulatory Filings 2006

Jun 28, 2006

News Details

Corporate | 28 June 2006 10:00

4SC announces further research collaboration with Solvay

Planegg-Martinsried, Germany, 28 June 2006 – 4SC AG (Frankfurt, Prime Standard: VSC), a drug discovery and development company specialising in research and development of therapeutic agents announced a research collaboration with Solvay Pharmaceuticals GmbH today.

The goal of the collaboration is the identification of new molecules, which bind to a certain illness-relevant target structure provided by Solvay, and thus building a basis for further development of drug candidates. By means of a proprietary, computer-based High-Throughput Screening technology, a selection of active substances from 4SC are prepared, which are then examined by Solvay in biological tests.

A first project with a similar project sequence was already agreed upon between 4SC and Solvay last year and successfully completed in December 2005. Financial details were not made available.

‘We are very impressed with the quality and the remarkable hit-rate of our first project with 4SC and we look forward to working together further,’ announced Dr. Dieter Ziegler, Discovery Program Manager Cardiology at Solvay.

‘The successful completion of the first project with Solvay is a further proof of the increased recognition of our virtual High-Throughput Screening technology,’ explained Dr. Ulrich Dauer, CEO of 4SC. ‘Therefore, we are very pleased to have attained another collaboration partner with Solvay and to be able to further expand our collaborative efforts.’

About 4SC

4SC AG (ISIN DE0005753818) has been listed in the Prime Standard of Frankfurt Stock Exchange since 15 December 2005. Founded in 1997 and now with a staff of 53, the company develops novel drug candidates for inflammatory diseases and cancer using a cheminformatics based technology platform. Traditional high throughput screening of therapeutic agents has been transferred from the lab to the computer. Thus, the company offers substantial cost and time advantages as well as increased success rates in drug development. 4SC AG uses its patented technology platform to create a sustainable product pipeline for active agents that are developed in early clinical phases (‘proof of concept’) and subsequently result in upfront and milestone payments as well as participation in sales generated by out-licensed products to the pharmaceutical industry. The pipeline currently has five projects, the first of which, on the treatment of rheumatoid arthritis, has successfully completed clinical phase I. Preparations for the conduct of the IIa clinical phase are well under way. A further one to two other product candidates should go into clinical development in 2006. Furthermore, the company has its technology platform in co-operation projects with biotech and pharma companies and is already generating initial revenues.

**About Solvay Pharmaceuticals

**SOLVAY PHARMACEUTICALS is a research driven group of companies that constitute the global pharmaceutical business of the SOLVAY Group with headquarters in Brussels. Seeking to fulfill carefully selected, unmet medical needs in the therapeutic areas of neuroscience, cardio-metabolic, influenza vaccines, pancreatic enzymes, gastroenterology and men’s and women’s health, it employs around 10 000 people worldwide. For more information, visit www.solvaypharmaceuticals.com

This document may contain projections or estimates relating to plans and objectives relating to our future operations, products, or services; future financial results; or assumptions underlying or relating to any such statements; each of which constitutes a forward-looking statement subject to risks and uncertainties, many of which are beyond our control. Actual results could differ materially, depending on a number of factors.